The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Current and experimental treatments of Parkinson disease: A guide for neuroscientists
Open accessAbstract
Over a period of more than 50 years, the symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been optimized using pharmacotherapy, deep brain stimulation, and physiotherapy. The arsenal of pharmacotherapies includes L‐Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)‐B and catechol‐o‐methyltransferase (COMT), and amantadine. In the later course of the disease, motor complications occur, at which stage different oral formulations of L‐Dopa or dopamine agonists with long half‐life, a transdermal application or parenteral pumps for continuous drug supply can be subscribed. Alternatively, the patient is offered deep brain stimulation of the subthalamic nucleus (STN) or the internal part of the globus pallidus (GP i). For a more efficacious treatment of motor complications, new formulations of L‐Dopa, dopamine agonists, and amantadine as well as new MAO‐B and COMT inhibitors are currently tested in clinical trials, and some of them already yielding positive results in phase 3 trials. In addition, non‐dopaminergic agents have been tested in the early clinical phase for the treatment of motor fluctuations and dyskinesia, including adenosine A2A antagonists (istradefylline, preladenant, and tozadenant) and modulators of the metabolic glutamate receptor 5 (mG luR5 ‐ mavoglurant) and serotonin (eltoprazine) receptors. Recent clinical trials testing coenzyme Q10, the dopamine agonist pramipexole, creatine monohydrate, pioglitazone, or AAV‐mediated gene therapy aimed at increasing expression of neurturin, did not prove efficacious. Treatment with nicotine, caffeine, inosine (a precursor of urate), and isradipine (a dihydropyridine calcium channel blocker), as well as active and passive immunization against α‐synuclein and inhibitors or modulators of α‐synuclein‐aggregation are currently studied in clinical trials. However, to date, no disease‐modifying treatment is available. We here review the current status of treatment options for motor and non‐motor symptoms, and discuss current investigative strategies for disease modification. This review provides basic insights, mainly addressing basic scientists and non‐specialists. It stresses the need to intensify therapeutic PD research and points out reasons why the translation of basic research to disease‐modifying therapies has been unsuccessful so far. image The symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been constantly optimized using pharmacotherapy (L‐Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)‐B and catechol‐o‐methyltransferase (COMT), and amantadine), deep brain stimulation, and physiotherapy. For a more efficacious treatment of motor complications, new formulations of L‐Dopa, dopamine agonists, and amantadine as well as new MAO‐B and COMT inhibitors are currently tested in clinical trials. Non‐dopaminergic agents have been tested in the early clinical phase for the treatment of motor fluctuations and dyskinesia. Recent clinical trials testing coenzyme Q10, the dopamine agonist pramipexole, creatine monohydrate, pioglitazone, or AAV‐mediated gene therapy aimed at increasing expression of neurturin, did not prove efficacious. Treatment with nicotine, caffeine, and isradipine – a dihydropyridine calcium channel blocker – as well as active and passive immunization against α‐synuclein and inhibitors of α‐synuclein‐aggregation are currently studied in clinical trials. However, to date, no disease‐modifying treatment is available for PD. We here review the current status of treatment options and investigative strategies for both motor and non‐motor symptoms. This review stresses the need to intensify therapeutic PD research and points out reasons why the translation of basic research to disease‐modifying therapies has been unsuccessful so far. This article is part of a special issue on Parkinson disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
A Randomized Trial of Deep-Brain Stimulation for Parkinson's Disease
Deuschl, G., Schade-Brittinger, C., Krack, P., Volkmann, J., Schäfer, H., Bötzel, K., Daniels, C., Deutschländer, A., Dillmann, U., Eisner, W., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060281 · Cited by 2,944
Self-citationLevodopa and the Progression of Parkinson's Disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,821
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
MDS research criteria for prodromal Parkinson's disease
Berg, D., Postuma, R. B., Adler, C. H., Bloem, B. R., Chan, P., Dubois, B., Gasser, T., Goetz, C. G., Halliday, G., Joseph, L., et al. (2015) · Movement Disorders · doi:10.1002/mds.26431 · Cited by 1,309
Self-citationGoedert, M., Spillantini, M. G., Del Tredici, K., & Braak, H. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.242 · Cited by 1,190
Seppi, K., Weintraub, D., Coelho, M., Perez‐Lloret, S., Fox, S. H., Katzenschlager, R., Hametner, E., Poewe, W., Rascol, O., Goetz, C. G., et al. (2011) · Movement Disorders · doi:10.1002/mds.23884 · Cited by 1,141
Luk, K. C., Kehm, V. M., Zhang, B., O’Brien, P., Trojanowski, J. Q., & Lee, V. M. Y. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112457 · Cited by 1,100
Effect of Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198911163212004 · Cited by 917
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
Olanow, C. W., Rascol, O., Hauser, R., Feigin, P. D., Jankovic, J., Lang, A., Langston, W., Melamed, E., Poewe, W., Stocchi, F., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809335 · Cited by 901
Pramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trial
Holloway, R. G., Shoulson, I., Kieburtz, K. D., McDermott, M., Tariot, P. N., Kamp, C., Day, D., Shinaman, A., Fahn, S., Lang, A. E., et al. (2000) · JAMA · Cited by 798
Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A Randomized Controlled Trial
Parkinson Study Group (2000) · JAMA · doi:10.1001/jama.284.15.1931 · Cited by 767
Odekerken, V. J., van Laar, T., Staal, M. J., Mosch, A., Hoffmann, C. F., Nijssen, P. C., Beute, G. N., van Vugt, J. P., Lenders, M. W., Contarino, M. F., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70264-8 · Cited by 763
Olanow, C. W., Kieburtz, K., Odin, P., Espay, A. J., Standaert, D. G., Fernandez, H. H., Vanagunas, A., Othman, A. A., Widnell, K. L., Robieson, W. Z., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70293-x · Cited by 716
Rascol, O., Brooks, D., Melamed, E., Oertel, W., Poewe, W., Stocchi, F., & Tolosa, E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71083-7 · Cited by 641
Self-citationFox, S. H., Katzenschlager, R., Lim, S., Ravina, B., Seppi, K., Coelho, M., Poewe, W., Rascol, O., Goetz, C. G., & Sampaio, C. (2011) · Movement Disorders · doi:10.1002/mds.23829 · Cited by 523
A Controlled, Randomized, Delayed-Start Study of Rasagiline in Early Parkinson Disease
(2004) · Archives of Neurology · doi:10.1001/archneur.61.4.561 · Cited by 485
Wagner, J., Ryazanov, S., Leonov, A., Levin, J., Shi, S., Schmidt, F., Prix, C., Pan-Montojo, F., Bertsch, U., Mitteregger-Kretzschmar, G., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1114-9 · Cited by 457
Karpinar, D. P., Balija, M. B. G., Kügler, S., Opazo, F., Rezaei‐Ghaleh, N., Wender, N., Kim, H., Taschenberger, G., Falkenburger, B. H., Heise, H., et al. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.257 · Cited by 432
Self-citationStuendl, A., Kunadt, M., Kruse, N., Bartels, C., Moebius, W., Danzer, K. M., Mollenhauer, B., & Schneider, A. (2016) · Brain · doi:10.1093/brain/awv346 · Cited by 428
(2005) · Archives of Neurology · doi:10.1001/archneur.62.2.241 · Cited by 418
Pathological α‐synuclein in gastrointestinal tissues from prodromal Parkinson disease patients
Stokholm, M. G., Danielsen, E. H., Hamilton‐Dutoit, S. J., & Borghammer, P. (2016) · Annals of Neurology · doi:10.1002/ana.24648 · Cited by 415
The Parkinson Study Group QE3 Investigators, Beal, M. F., Oakes, D., Shoulson, I., Henchcliffe, C., Galpern, W. R., Haas, R., Juncos, J. L., Nutt, J. G., Voss, T. S., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.131 · Cited by 408
PD MED Collaborative Group (2014) · The Lancet · doi:10.1016/s0140-6736(14)60683-8 · Cited by 407
Plasma Urate and Risk of Parkinson's Disease
Weisskopf, M., O'Reilly, E., Chen, H., Schwarzschild, M., & Ascherio, A. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm127 · Cited by 390
Cigarette smoking and protection from Parkinson's disease: False association or etiologic clue?
Morens, D. M., Grandinetti, A., Reed, D., White, L. R., & Ross, G. W. (1995) · Neurology · doi:10.1212/wnl.45.6.1041 · Cited by 370
Morais, V. A., Haddad, D., Craessaerts, K., De Bock, P.-J., Swerts, J., Vilain, S., Aerts, L., Overbergh, L., Grünewald, A., Seibler, P., et al. (2014) · Science · doi:10.1126/science.1249161 · Cited by 362
Parkinson Study Group (1996) · Annals of Neurology · doi:10.1002/ana.410390107 · Cited by 356
Urate as a Predictor of the Rate of Clinical Decline in Parkinson Disease
Ascherio, A. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.247 · Cited by 354
Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study
Aarsland, D. (2002) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.72.6.708 · Cited by 341
Cilia, R., Akpalu, A., Sarfo, F. S., Cham, M., Amboni, M., Cereda, E., Fabbri, M., Adjei, P., Akassi, J., Bonetti, A., et al. (2014) · Brain · doi:10.1093/brain/awu195 · Cited by 339
Mortality in Parkinson's disease: A systematic review and meta‐analysis
Macleod, A. D., Taylor, K. S. M., & Counsell, C. E. (2014) · Movement Disorders · doi:10.1002/mds.25898 · Cited by 328
Smoking, nicotine and Parkinson's disease
Quik, M. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.06.008 · Cited by 324
Burn, D., Emre, M., McKeith, I., De Deyn, P. P., Aarsland, D., Hsu, C., & Lane, R. (2006) · Movement Disorders · doi:10.1002/mds.21077 · Cited by 310
Serum uric acid levels and the risk of Parkinson disease
de Lau, L. M. L., Koudstaal, P. J., Hofman, A., & Breteler, M. M. B. (2005) · Annals of Neurology · doi:10.1002/ana.20663 · Cited by 301
Caffeine for treatment of Parkinson disease: A randomized controlled trial
Postuma, R. B., Lang, A. E., Munhoz, R. P., Charland, K., Pelletier, A., Moscovich, M., Filla, L., Zanatta, D., Rios Romenets, S., Altman, R., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318263570d · Cited by 298
Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin
Dasgupta, P., Kinkade, R., Joshi, B., DeCook, C., Haura, E., & Chellappan, S. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509313103 · Cited by 295
Warren Olanow, C., Bartus, R. T., Baumann, T. L., Factor, S., Boulis, N., Stacy, M., Turner, D. A., Marks, W., Larson, P., Starr, P. A., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24436 · Cited by 287
Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial
(2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00144-1 · Cited by 286
Shannon, K. M., Bennett, J. P., Friedman, J. H., & the Pramipexole Study Group (1997) · Neurology · doi:10.1212/wnl.49.3.724 · Cited by 281
Ropinirole for the treatment of early Parkinson's disease
Adler, C. H., Sethi, K. D., Hauser, R. A., Davis, T. L., Hammerstad, J. P., Bertoni, J., Taylor, R. L., Sanchez-Ramos, J., O'Brien, C. F., & Ropinirole Study Group (1997) · Neurology · doi:10.1212/wnl.49.2.393 · Cited by 281
Ravina, B. (2005) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2004.050682 · Cited by 273
Hauser, R. A., Rascol, O., Korczyn, A. D., Jon Stoessl, A., Watts, R. L., Poewe, W., De Deyn, P. P., & Lang, A. E. (2007) · Movement Disorders · doi:10.1002/mds.21743 · Cited by 252
Disease‐modifying strategies for Parkinson's disease
Kalia, L. V., Kalia, S. K., & Lang, A. E. (2015) · Movement Disorders · doi:10.1002/mds.26354 · Cited by 251
Are synucleinopathies prion-like disorders?
Angot, E., Steiner, J. A., Hansen, C., Li, J.-Y., & Brundin, P. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70213-1 · Cited by 251
Costa, J., Lunet, N., Santos, C., Santos, J., & Vaz-Carneiro, A. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091525 · Cited by 247
Cutaneous neuropathy in Parkinson’s disease: a window into brain pathology
Doppler, K., Ebert, S., Üçeyler, N., Trenkwalder, C., Ebentheuer, J., Volkmann, J., & Sommer, C. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1284-0 · Cited by 238
Smoking and Parkinson’s disease: A dose–response relationship
Gorell, J. M., Rybicki, B. A., Johnson, C. C., & Peterson, E. L. (1999) · Neurology · doi:10.1212/wnl.52.1.115 · Cited by 224
Rascol, O., Fitzer-Attas, C. J., Hauser, R., Jankovic, J., Lang, A., Langston, J. W., Melamed, E., Poewe, W., Stocchi, F., Tolosa, E., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70073-4 · Cited by 212
Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study
Oertel, W. H., Wolters, E., Sampaio, C., Gimenez‐Roldan, S., Bergamasco, B., Dujardin, M., Grosset, D. G., Arnold, G., Leenders, K. L., Hundemer, H., et al. (2006) · Movement Disorders · doi:10.1002/mds.20724 · Cited by 210
Self-citationKieburtz, K., Tilley, B. C., Elm, J. J., Babcock, D., Hauser, R., Ross, G. W., Augustine, A. H., Augustine, E. U., Aminoff, M. J., Bodis-Wollner, I. G., et al. (2015) · JAMA · doi:10.1001/jama.2015.120 · Cited by 207
Long-term Effect of Initiating Pramipexole vs Levodopa in Early Parkinson Disease
Parkinson Study Group CALM Cohort Investigators (2009) · Archives of Neurology · doi:10.1001/archneur.66.1.nct90001 · Cited by 205
Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial
Schapira, A. H., McDermott, M. P., Barone, P., Comella, C. L., Albrecht, S., Hsu, H. H., Massey, D. H., Mizuno, Y., Poewe, W., Rascol, O., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70117-0 · Cited by 203
Evans, A. H. (2005) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.065417 · Cited by 185
Smoking and Parkinson’s disease in twins
Tanner, C. M., Goldman, S. M., Aston, D. A., Ottman, R., Ellenberg, J., Mayeux, R., & Langston, J. W. (2002) · Neurology · doi:10.1212/wnl.58.4.581 · Cited by 182
Vilas, D., Iranzo, A., Tolosa, E., Aldecoa, I., Berenguer, J., Vilaseca, I., Martí, C., Serradell, M., Lomeña, F., Alós, L., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00080-6 · Cited by 177
Parkinson Study Group (1996) · Annals of Neurology · doi:10.1002/ana.410390106 · Cited by 170
Deep brain stimulation mechanisms: the control of network activity via neurochemistry modulation
McIntyre, C. C., & Anderson, R. W. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13649 · Cited by 161
Parkinson disease and smoking revisited: Ease of quitting is an early sign of the disease
Ritz, B., Lee, P.-C., Lassen, C. F., & Arah, O. A. (2014) · Neurology · doi:10.1212/wnl.0000000000000879 · Cited by 160
Nicotine and Parkinson's disease: implications for therapy
Quik, M., O'Leary, K., & Tanner, C. M. (2008) · Movement Disorders · doi:10.1002/mds.21900 · Cited by 154
Skin nerve misfolded α‐synuclein in pure autonomic failure and P arkinson disease
Donadio, V. A., Incensi, A., Piccinini, C., Cortelli, P., Giannoccaro, M. P., Baruzzi, A., & Liguori, R. (2015) · Annals of Neurology · doi:10.1002/ana.24567 · Cited by 146
Chronic oral nicotine treatment protects against striatal degeneration in MPTP‐treated primates
Quik, M., Parameswaran, N., McCallum, S. E., Bordia, T., Bao, S., McCormack, A. L., Kim, A., Tyndale, R. F., Langston, J. W., & Monte, D. A. D. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04078.x · Cited by 137
Transdermal nicotine in PD: A randomized, double-blind, placebo-controlled study
Vieregge, A., Sieberer, M. G., Jacobs, H., Hagenah, J., & Vieregge, P. (2001) · Neurology · doi:10.1212/wnl.57.6.1032 · Cited by 133
Levin, J., Schmidt, F., Boehm, C., Prix, C., Bötzel, K., Ryazanov, S., Leonov, A., Griesinger, C., & Giese, A. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1265-3 · Cited by 132
Cabergoline in the treatment of early parkinson's disease
Rinne, U. K., Bracco, F., Chouza, C., Dupont, E., Gershanik, O. S., Martí-Massó, J. F., Montastruc, J., MARSDEN, C. D., Dubini, A., Orlando, N., et al. (1997) · Neurology · doi:10.1212/wnl.48.2.363 · Cited by 130
Rivastigmine for mild cognitive impairment in Parkinson disease: A placebo‐controlled study
Mamikonyan, E., Xie, S. X., Melvin, E., & Weintraub, D. A. (2015) · Movement Disorders · doi:10.1002/mds.26236 · Cited by 127
Deuschl, G., Schüpbach, M. W. M., Knudsen, K., Pinsker, M. O., Cornu, P., Rau, J., Agid, Y., & Schade‐Brittinger, C. (2012) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2012.07.004 · Cited by 126
Chronic high dose transdermal nicotine in Parkinson's disease: an open trial
Villafane, G., Césaro, P., Rialland, A., Baloul, S., Azimi, S., Bourdet, C., Houezec, J. L., Macquin‐Mavier, I., & Maison, P. (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2007.01949.x · Cited by 118
Smoking and Parkinson's disease: Does nicotine affect α-synuclein fibrillation?
Hong, D.-P., Fink, A. L., & Uversky, V. N. (2008) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2008.09.026 · Cited by 109
Gong, L., Zhang, Q., Zhang, N., Hua, W., Huang, Y., Di, P., Huang, T., Xu, X., Liu, C., Hu, L., et al. (2012) · Journal of Neurochemistry · doi:10.1111/jnc.12038 · Cited by 107
Lemay, S., Chouinard, S., Blanchet, P. J., Masson, H., Soland, V., Beuter, A. C., & Bédard, M. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(03)00172-6 · Cited by 102
Mitochondrial dysfunction in movement disorders
Schulz, J. B., & Beal, M. F. (1994) · Current Opinion in Neurology · doi:10.1097/00019052-199408000-00010 · Cited by 92
Self-citationThe short-term effect of nicotine chewing gum in patients with parkinson's disease
Clemens, P., Baron, J. A., Coffey, D., & Reeves, A. G. (1995) · Psychopharmacology · doi:10.1007/bf02245195 · Cited by 84
Nrf2 Signaling Contributes to the Neuroprotective Effects of Urate against 6-OHDA Toxicity
Zhang, N., Shu, H., Huang, T., Zhang, Q., Li, D., Zhang, G., Peng, X., Liu, C., Luo, W., & Hu, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100286 · Cited by 65
Caffeine consumption and risk of dyskinesia in CALM ‐ PD
Wills, A.-M. A., Eberly, S. W., Tennis, M. K., Lang, A. E., Messing, S. P., Togasaki, D. M., Tanner, C. M., Kamp, C., Chen, J., Oakes, D., et al. (2013) · Movement Disorders · doi:10.1002/mds.25319 · Cited by 61
Oral I nosine P ersistently E levates P lasma antioxidant capacity in P arkinson's disease
Bhattacharyya, S., Bakshi, R., Logan, R. A., Ascherio, A., Macklin, E. A., & Schwarzschild, M. A. (2016) · Movement Disorders · doi:10.1002/mds.26483 · Cited by 43
Activity enhances dopaminergic long-duration response in Parkinson disease
Kang, U. J., Auinger, P., Fahn, S., Oakes, D., Shoulson, I., Kieburtz, K. D., Rudolph, A., MAREK, K. L., Seibyl, J. P., Lang, A. E., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31824f8056 · Cited by 28
Parkinson’s Disease Protects Against Smoking?
Allam, M. F., Campbell, M. J., del Castillo, A. S., & Navajas, R. F. (2004) · Behavioural Neurology · doi:10.1155/2004/516302 · Cited by 27
Tsukada, H., Miyasato, K., Harada, N., Nishiyama, S., Fukumoto, D., & Kakiuchi, T. (2005) · Synapse · doi:10.1002/syn.20157 · Cited by 14
Effects of selegiline and rasagiline on disease progression in Parkinson’s disease
Schulz, J. B. (2012) · Basal Ganglia · doi:10.1016/j.baga.2012.08.003 · Cited by 4
Self-citation
Cited by
Parkinson’s Disease: From Pathogenesis to Pharmacogenomics
Cacabelos, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030551 · Cited by 555
Glutamate-induced excitotoxicity in Parkinson's disease: The role of glial cells
Iovino, L., Tremblay, M. E., & Civiero, L. (2020) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2020.07.011 · Cited by 374
C-terminal calcium binding of α-synuclein modulates synaptic vesicle interaction
Lautenschläger, J., Stephens, A. D., Fusco, G., Ströhl, F., Curry, N., Zacharopoulou, M., Michel, C. H., Laine, R., Nespovitaya, N., Fantham, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03111-4 · Cited by 334
Monzani, E., Nicolis, S., Dell'Acqua, S., Capucciati, A., Bacchella, C., Zucca, F. A., Mosharov, E. V., Sulzer, D., Zecca, L., & Casella, L. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201811122 · Cited by 271
Kjaergaard, J., Hatfield, S., Jones, G., Ohta, A., & Sitkovsky, M. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1700850 · Cited by 132
Metadata
- Authors
- Oertel, W., & Schulz, J. B.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2016-08-30
- Volume
- 139
- Issue
- S1
- Pages
- 325-337
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2516348886
- Cited by
- 369
- References
- 80
- FWCI
- 27.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.